Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

It’s the latest step from pharmacy benefit managers to respond to relentless criticism from politicians and regulators over ...

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.

The FTC's first report drew a strong response from the PBM sector, with lawsuits filed in both directions. The FTC has accused the big three of operating a "perverse drug rebate system," while the ...

As the 119th Congress convenes, policymakers have a historic opportunity to lower prescription drug prices for Americans. As ...

The lawsuit – which has been anticipated since the FTC published a damning report on the PBM sector in July – names CVS Health's Caremark, UnitedHealth Group's Optum, and Cigna's Express ...

Edward Jones, a financial services firm, upgraded CVS Health (NYSE:CVS) stock from Hold to Buy. The upgrade comes as the stock, which InvestingPro analysis shows is currently undervalued, has posted a ...